ViiV Healthcare filed lawsuits in U.S. and Canada alleging patent infringement by Gilead Sciences Inc. for its newly approved HIV-1 treatment Biktarvy.
The company, majority owned by GlaxoSmithKline plc with Pfizer Inc. and Shionogi & Co. Ltd. as shareholders, said Biktarvy infringed patents on its HIV treatment dolutegravir, or Tivicay, and other compounds with the drug's "unique chemical scaffold," according to a news release.
The lawsuits come after the U.S. Food and Drug Administration approved Biktarvy, a once-daily single tablet regimen for treating HIV-1 infection.
The U.S. case was filed in the U.S. District Court for the District of Delaware. The Canadian case was filed in the Canadian Federal Court in Toronto.
